---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116646"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:48:32.038194+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharma reports Q3 2023 results; NDA submitted for etripamil in PSVT

## Summary
- Cash $75.7M as of Sep 30, 2023; expected to fund operations into mid-2025.
- Q3 operating loss $15.4M vs $15.0M prior year; R&D expense down to $6.7M.
- NDA for etripamil (CARDAMYST) in PSVT submitted to FDA; acceptance decision by end of 2023.
- Positive Phase 2 ReVeRA data for etripamil in AFib-RVR presented at AHA; Phase 3 program to start mid-2024.
- Commercial expense rose to $4.4M in Q3 from $2.7M prior year, building pre-launch capabilities.

## SEC filing metadata
- accession: 0001104659-23-116646
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465923116646/0001104659-23-116646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465923116646/tm2330492d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116646
- JSON: https://secwatch.observer/filing/0001104659-23-116646.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116646.txt

## Key facts
- Earnings Releases
  Milestone Pharmaceuticals Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023, which also provided a clinical and corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1408443/000110465923116646/0001104659-23-116646-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.